Expert Analysis and Commentary on
Issues of Importance to Institutional Investors

 
Featured
Pomerantz: A Dedication to Education
$12 Million Settlement for PureCycle Investors
$7.5 Million Settlement for Faraday Investors
Pomerantz Finalizes Settlement on Behalf of Ginkgo Bioworks Investors
Pomerantz Saves an NYC Homeless Facility
Betting Against the House and Wynn-ing
Pomerantz Settles Case Alleging “Dark Practices”
“AI Washing” – The New Deceptive Marketing Technique
Pomerantz Achieves Settlement with Emergent BioSolutions
Pomerantz Holds London Corporate Governance Roundtable With Sir Tony Blair
Supreme Court Further Curtails Power of Administrative Agencies
Section 12 and Fundraising Via Digital Assets
Event-Driven Securities Litigation: an Interview with Marc I. Gross
Pomerantz Settles Ground-Breaking Case Against Perrigo for $97 Million
Delaware Proposes Dramatic Corporate Law Amendments in Response to Moelis Decision
DOJ Rolls Out Pilot Program for Voluntary Disclosures
Pomerantz Secures $47 Million Settlement for Defrauded Novavax Investors
Curiouser and Curiouser – the Changing Dynamic of Shareholder-Corporate Engagement
SEC Passes Climate Disclosure Rules After Two-Year Wait
SEC Finalizes Rules Relating to SPACs, Shell Companies, and De-SPAC Transactions
Pomerantz Scores Major Victory in Investor Suit Against Y-mAbs
The Future of Section 10(b) Claims Premised on Violations of Item 303 Looks Uncertain
Court Denies Motion to Dismiss Claims Against Nikola Corporation
Artificial Intelligence in Public Stock Trading
Pomerantz Resolves Opt-Out Actions with Teva Pharmaceuticals
The FDIC’s Proposed Standards for Corporate Governance and Risk Management
What’s in an Acronym? (Or, Can Bill Ackman “SPARC” a Fix to SPACs?)
The Future of Item 303-Based 10b-5 Claims
Goldman Sachs Cert Redux
Pomerantz Defeats Motion to Dismiss in In re Bed Bath and Beyond Sec. Litig.

Search previous Pomerantz Monitor issues: